Immune Medicines
Lilly Invests $85M Upfront in Repertoire Immune Medicines for Autoimmune Therapies Partnership
Eli Lilly; Repertoire Immune Medicines; autoimmune diseases; DECODE platform; tolerizing therapies; $85M upfront; $1.84B milestones; Flagship Pioneering
Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M
Repertoire, genentech, Autoimmune Diseases, Immune Medicines, Partnership